Article
Repurposing CRISPR/Cas9 for in situ functional assays.
Genes & development - 1 Dec 2013
Malina Abba, Mills John R, Cencic Regina, Yan Yifei, Fraser James, Schippers Laura M, Paquet Marilène, Dostie Josée, Pelletier Jerry
Abstract excerpt
RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle tar...
Topics
- Animals
- CRISPR-Associated Proteins
- Clustered Regularly Interspaced Short Palindromic Repeats
- Female
- Gene Targeting
- Genes, p53
- Genetic Techniques
- Genome
- INDEL Mutation
- Kaplan-Meier Estimate
- Lentivirus
- Lymphoma
- Mice
- Mice, Inbred C57BL
- Mutation
- Reproducibility of Results